Nucleix Advances Epigenetic Tests for Bladder, Lung Cancers in Europe, Eyes US, China

NEW YORK (GenomeWeb) – Molecular diagnostics firm Nucleix continues to advance its menu of epigenetic tests for cancer.

The Israeli firm recently announced the results of a multicenter study of its Bladder EpiCheck test in addition to netting €2.5 million ($2.9 million) in EU funding to develop a lung cancer assay.

Get the full story with
GenomeWeb Premium Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Be the first to comment

Leave a Reply

Your email address will not be published.


*